Jefferies Immuno-Oncology SummitApril 15, 2015

2 K I T E P H A R M A , I N C .

Forward Looking Statements / Safe Harbor

To the extent statements contained in this presentation are not descriptions of historical facts regarding Kite Pharma, Inc. (Kite, we, us, or our), they are forward-looking statements reflecting managements current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industrys actual results, levels or activity, performance, or achievements to be materially different from those anticipated bysuch statements. You can identify forward-looking statements by words such as anticipate, believe, could, estimate, expect, intend, may, plan, potential, predict, project, should, will, would or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding: (i) the success, cost and timing of our product development activities and clinical trials; (ii) the ability and willingness of the National Cancer Institute (NCI) to continue research anddevelopment activities relating to our product candidates; (iii) our ability to obtain and maintain regulatory approval of KTE-C19 and any other product candidates; (iv) our ability to obtain funding for our operations and further development and commercialization of our product candidates; (v) our plans to research and discover additional product candidates, including through our acquired subsidiary in Amsterdam; (vi) our ability to develop, manufacture and commercialize our product candidates; (vii) the size and growth potential of the markets for our product candidates, and our ability to serve those markets; (viii) the rate and degree of market acceptance of our product candidates; (ix) our ability to attract and retain key scientific or management personnel; (x) the anticipated timing of clinical data availability; and (xi) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, including without limitation in its Form 10-K for the year ended December 31, 2014. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

3 K I T E P H A R M A , I N C .

Kite Pharma Overview

Corporate Update

CAR & TCR Pipeline

KTE-C19 in B Cell Malignancy

Manufacturing

Advancing eACT

4 K I T E P H A R M A , I N C .

Redefining Cancer Therapy with Gene-based Cellular Immunotherapy

Headquartered in Santa Monica, CA with a European facility in Amsterdam, NL

Fully integrated R&D and Manufacturing capabilities

Strong IP for Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) products

Strategic partnerships

Robust pipeline of CAR and TCR products with multiple products in clinical trials

KTE-C19 entering pivotal trials in B-cell malignancies under Kite-sponsored IND

Proprietary, low-cost and rapid manufacturing process

Ongoing Complete Response 15+ months in a patient with

chemo-refractory PMBCL

5 K I T E P H A R M A , I N C .

Experienced Senior Leadership with Proven Track Records for Success

Arie Belldegrun, MD, FACSFounder, Chairman, President, CEO

UCLA, Teva, Arno, Cougar, Agensys, NCI

Cynthia M. Butitta, MBACOO and CFO

NextWave, Telik, Connetics

David D. Chang, MD, Ph.DEVP R&D, CMO

Amgen, UCLA

Helen KimEVP, Business Development

NGM Biopharmaceuticals, Kosan, Onyx, Chiron

Margo R. Roberts, Ph.DChief Scientific Officer

University of Virginia, Cell Genesys

Ton N. M. Schumacher, Ph.DChief Scientific Officer Kite Pharma EU

Netherlands Cancer Institute (NKI)

Salah D. Kivlighn, Ph.DVP, Marketing

MedImmune, NABI Biopharmaceuticals, Merck

Marc Better, Ph.DVP, Product Sciences

Boehringer Ingelheim, Amgen, Abgenix, XOMA

Jeffrey Wiezorek, MD, MSVP, Clinical Development

Amgen, UCLA, California Institute of Technology

Rizwana F. Sproule, Ph.DVP, Regulatory Affairs

Amgen, SmithKline Beecham

6 K I T E P H A R M A , I N C .

Scientific Advisory Board: World Leaders in Cancer Immunotherapy

Owen Witte, M.D. Chair Distinguished Professor of Microbiology,

Immunology and Molecular Genetics, UCLA

Howard Hughes Investigator

Member, National Academy of Sciences

Inder Verma, Ph.D. Irwin and Joan Jacobs Chair of Exemplary

Science and American Cancer Society Professor of Molecular Biology, The Salk Institute

Member, National Academy of Sciences

James Economou, M.D., Ph.D. Professor of Surgery, Microbiology,

Immunology and Molecular Genetics and Molecular and Medical Pharmacology, UCLA

Vice Chancellor of Research, UCLA

Antoni Ribas, M.D., Ph.D. Director, Tumor Immunology Program,

Jonsson Comprehensive Cancer Center, UCLA

Professor of Medicine, Professor of Surgery and Professor of Molecular and Medical Pharmacology, UCLA

Ronald Levy, M.D. Robert K Summy and Helen K Summy

Professor of Medicine, Stanford University

Director, Lymphoma Program, Stanford University

Member, National Academy of Sciences

Donald Kohn, M.D. Professor of Microbiology, Immunology and

Molecular Genetics & Pediatric Hematology/Oncology, UCLA

Director, Human Gene and Cell Therapy Program, UCLA

Member, Broad Stem Cell Research Center & Jonsson Comprehensive Cancer Center

7 K I T E P H A R M A , I N C .

Building a Robust IP Estate with Scientific Leadersin Gene-Based Cellular Immunotherapy

Broadest claims for all scFv-based CAR constructs

Expanding portfolio of TCR and CAR products

Pioneering neo-antigen TCR products

Proprietary manufacturing processes

8 K I T E P H A R M A , I N C .

Expanding Pipeline Through Strategic Collaborations and Internal R&D

CRADA Pioneering research

Product & process design

Early clinical evaluation

Internal R&D and Business Dev. R&D and Manufacturing in SM, CA

TCR Discovery Research in Amsterdam

Strong relationship with the Netherlands Cancer Institute provides access to investigators, clinical sites and manufacturing facilities in Europe.

Multi-Target Partnership Amgens validated oncology targets

Kites CAR design, IND enabling research & eACTTM manufacturing

9 K I T E P H A R M A , I N C .

Actively Investigating CARs and TCRs that Target Multiple Tumor Types

TARGET TUMOR TYPES

CD19Non-Hodkins Lymphoma, including DLBCL, PMBCL, TFL, and

Leukemias, including MCL, CLL and ALL

EGFRvIII Glioblastoma, head and neck cancer, melanoma

NY-ESO-1

Sarcoma, urothelial carcinoma, esophageal carcinoma, non-small cell lung cancer, breast

carcinoma, ovarian carcinoma, prostate carcinoma, multiple myeloma, hepatocellular

carcinoma, gastric cancer, head and neck cancer, pancreatic carcinoma, brain cancer,

colorectal carcinoma and melanoma

HPV-16 E6Head and neck cancer, cervical carcinoma, anal cancer, penile cancer, and various

aerodigestive tumorsHPV-16 E7

MAGE A3/A6 Urothelial carcinoma, non-small cell lung cancer, breast carcinoma, ovarian carcinoma,

prostate carcinoma, hepatocellular carcinoma, gastric cancer, head and neck cancer,

pancreatic carcinoma and melanomaMAGE A3

SSX2 Head and neck cancer, hepatocellular carcinoma, melanoma, prostate cancer, and sarcoma

Tumor Specific

Neo-AntigensSolid Tumors Potentially all carcinomas

Amgen

Collaboration

Targets

Heme Malignancies and Solid Tumors, such as AML, clear cell renal cell carcinoma and

multiple myeloma

Heme Malignancies Solid Tumors

10 K I T E P H A R M A , I N C .

Advancing eACT on Multiple FrontsSeven CAR and TCR programs in clinical testing

K I T E P H A R M A , I N C .

PROGRAM INDICATION PRE-IND PHASE 1 PHASE 2/3

Anti-CD19 CAR B Cell Malignancies

KTE-C19 CAR

NHL (DLBCL)

NHL (MCL)

CLL

ALL

EGFRvIII CAR Glioblastoma

NY-ESO-1 TCR Solid tumors

HPV-16 E6 TCR Cervical and

Head & Neck CancerHPV-16 E7 TCR

MAGE A3/A6

TCRSolid tumors

MAGE A3 TCR Solid tumors

SSX2 TCR Solid tumors

Amgen

Collaboration

Heme Malignancies

and Solid Tumors

Pivotal studies across 4 indications in 2015

Heme Malignancy

Solid Tumors

Other than the KTE-C19 and Amgen related programs, the clinical trials are being conducted by the NCI pursuant to our CRADA.

11 K I T E P H A R M A , I N C .

Laying the Foundation to Transform Cancer Therapy

Solid IP

First Product Launch in

2017 (anticipated)

Strategic Partnership

US/EU Presence

Proprietary Manufacturing

ProcessExperienced Team with

Proven Record of Success

RobustPipeline

(CAR & TCR)

Breakthrough Efficacy in KTE-C19

12 K I T E P H A R M A , I N C .

Kite Pharma Overview

Corporate Update

CAR & TCR Pipeline

KTE-C19 in B Cell Malignancy

Manufacturing

Advancing eACT

13 K I T E P H A R M A , I N C .

Kite CAR & TCR PlatformsRedirecting Immune Cells Against Cancer

Chimeric Antigen Receptor (CAR) Products T Cell Receptor (TCR) Products

Targets moleculeson the cell

surface

Targets molecules at or below the

cell surface

14 K I T E P H A R M A , I N C .

Chimeric Antigen ReceptorsModular Approach to Harness T Lymphocytes

Single-Chain Variable Fragment Specific for cell surface protein Target selection is critical

Co-Stimulatory DomainCD28 Induces IL-2 production and proliferation Protects T cells from activation induced cell

death and anergy Promotes Tcm expansion and survival

Transmembrane & Hinge Domains Impacts CAR expression Important for optimal CAR

function at immunologic synapse

Signaling Domain From TCR CD3z chain Provides essential activation

signal via ITAMs

1. Boesteanu and Katsikis, Seminars in immunology. Vol. 21, 20092. Volpin et al., doi: 10.3389/conf. fimmu. Vol. 999. 2013..

15 K I T E P H A R M A , I N C .

TCRs Aim at a Broad Spectrum of Therapeutic Tumor Targets

Kite Pharma is uniquely positioned to address an unmet need and target a large hidden opportunity

16 K I T E P H A R M A , I N C .

Building TCR FranchiseAddressing Both the Targets and HLA Haplotypes

NY-ESO-1 TCR (HLA-A2)

HPV-16 E6 TCR(HLA-A2)

Neo-antigens

MAGE A3 TCR(HLA-A1)

MAGE A3/A6 TCR

(HLA-DP4)

Targets

HLA

HLA..

Aberrantly expressed & elicit autologous T cell responses

MAGE, NY-ESO-1, SSX

Cancer Testis Antigens

(CTAg)

Viral antigens are unique

High-risk oncogenic viruses(e.g., HPV, EBV, HBV)

Viral Antigens

(VAg)

From acquired mutations in cancer

NOT present in normal cells

Neo-antigens

(NAg)

Kite Pharma EUs TCR-GENErator is an industry-leading R&D engine for rapid, high-throughput identification of TCR-based product candidates,

which could enter the clinic as early as 2017

17 K I T E P H A R M A , I N C .

Kite Pharma Overview

Corporate Update

CAR & TCR Pipeline

KTE-C19 in B Cell Malignancy

Manufacturing

Advancing eACT

18 K I T E P H A R M A , I N C .

Compelling Preliminary Evidence of Broad Anti-Tumor Activity in B-cell Malignancies

32 patients enrolled (29 evaluable), including largest dataset of anti-CD19 CAR in lymphoma

Emerging AE profile includes: Transient cytokine release syndrome Reversible neurotoxicity B cell aplasia

Response Rate 76% overall, 65% in DLBCL/PMBCL (n=17)

16 patients with ongoing response

12 patients with ongoing response over 1 year

3 patients were re-treated after progression; all in ongoing response (17+ to 52+ months)

Kochenderfer Blood 2012; Kochenderfer JCO 2014; Kochenderfer ASH 2014

Updated 12/2014

A patient with recurrent DLBCL post-SCT treated with CD-19 CAR T cells

19 K I T E P H A R M A , I N C .

Anti-CD19 CAR Treatment Achieves Complete Responses in Heavily Pretreated Patients with ALL

Lee et al Lancet 2014

Intention-to-TreatAnalysis

ALL (N=20)

Complete Response 14 (70%)

MRD negative Complete Response

12 (60%)

Allogeneic Transplant 10 (50%)

Relapse Post Allogeneic Transplant

0 (0%)

78.8%

51.6%Median follow

up = 10 mo

20 K I T E P H A R M A , I N C .

KTE-C19-101Phase 1/2 Trial in Refractory Aggressive NHL

Cohort 2: PMBCL and TFL(n=40)

Cohort 1: DLBCL(n=72)

DLBCL=Diffuse Large B-cell LymphomaPMBCL=Primary Mediastinal B-cell LymphomaTFL=Transformed Follicular Lymphoma

Pivotal Phase 2 Key Eligibility Criteria

Refractory DLBCL, PMBCL, TFL Measurable Disease ECOG 0-1

Primary Endpoint Objective Response Rate

Operations First patient enrolled H1 2015 Multi-center study (~25 sites) Interim analysis (cohort 1) after 50

patients Plan to file for accelerated

approval if compelling data

21 K I T E P H A R M A , I N C .

Lead Product Candidate, KTE-C19, Could Address Significant Unmet need in B Cell Malignancies

Indication Population PhaseFirst Subject

Enrolled

DLBCLPMBCL

TFL

Refractory or relapsed post

transplant

2(n=112)

1H 2015

MCL Relapsed/refractory 2 2015

ALL Relapsed/refractory 2 2015

CLL Relapsed/refractory 2 2015

If Phase 2 data are compelling, potential for Accelerated Approvals and product launch in 2017 (DLBCL)

New Cases per Year (US)1,2

*Deaths per Year (US)2,3

1) American Cancer Society, 2014 Facts and Figures; 2) The Leukemia and Lymphoma Society, Facts 2013 3) Adv Immunol. 2005; 87: 163208.

10,00022,000

4,600 15,700

1,400 6,000

22 K I T E P H A R M A , I N C .

Streamlined and Rapid eACT Manufacturing Process for KTE-C19

Apheresis product shipped to CMO

Gene Transduction

Cell Expansion

Cryopreservation

T Cell Activation

Ready for bedside use

Single T cell stimulation of PBMC in human serum-free media

Streamlined process amenable to cGMP

Short duration of cell expansion enriches TCM population

Transportation logistics in place for multi-center clinical trial

CD45RA+CCR7+(Naive)

CD45RA-CCR7+(CM)

CD45RA-CCR7-(EM)

CD45RA+CCR7-(Eff)

0

20

40

60

80

All pts (1-15 inc)

* Differences between subsets statistically signifcant except for naive versus eff

% o

f C

AR

+ T

ce

lls

increasing differentiation

CD45

RA+

CCR7+

CD45

RA-

CCR7+

CD45

RA-

CCR7-

CD45

RA+

CCR7-

0

20

40

60

80

Pts 1-15, minus 8,9

% o

f C

AR

+ T

ce

lls

CD45

RA+

CCR7+

CD45

RA-

CCR7+

CD45

RA-

CCR7-

CD45

RA+

CCR7-

0

20

40

60

Pts 8,9 only

% o

f C

AR

+ T

ce

lls

N/Tscm CM EM Eff

N=13

23 K I T E P H A R M A , I N C .

Establishing Manufacturing Capabilities in Anticipation of KTE-C19 Launch in 2017

Developed a proprietary, cost-efficient manufacturing process for KTE-C19

Secured clinical supply with contract manufacturing

Established a GMP facility in Santa Monica, CA for additional clinical supply

Building out commercial facility in El Segundo, CA

Staffing fully integrated Manufacturing Operations

24 K I T E P H A R M A , I N C .

Kite Pharma Overview

Corporate Update

CAR & TCR Pipeline

KTE-C19 in B Cell Malignancy

Manufacturing

Advancing eACT

25 K I T E P H A R M A , I N C .

Advancing eACT on All Fronts

Lineage-specific targets (Heme malignancies)

Cancer-specific (CTAg, VAg, NAg) vs. Cancer-associated antigens

Target Selection

Human scFv; linker-spacer; co-stimulatory domain

High affinity TCR

Additional stimulatory signals

CAR/TCR Optimization

Limited ex vivo T cell expansion

Selected expansion of T cell subtypesManufacturing

Combination therapyTumor

Microenvironment

CRITICAL for T cell expansionConditioning

Chemotherapy

26 K I T E P H A R M A , I N C .

Maintaining the Momentum: Projected Milestones for the Next 12 Months

KTE-C19 IND accepted by FDA

Secure in-house clinical manufacturing site

Establish European presence

Build out commercial manufacturing capacity

Initiate KTE-C19 DLBCL pivotal study (1H) and additional studies

Obtain Breakthrough Therapy Designation in DLBCL

Present KTE-C19 data

File an IND relating to a TCR product

27 K I T E P H A R M A , I N C .

Multiple Clinical Trials Will Generate Meaningful Data that Will Drive Kite Global Development

Program1 Indication FSE2 Data Availability3

1 Anti-CD19 CAR B Cell Malignancies 2009 periodic update

2 KTE-C19 CAR

DLBCL H1 2015P1 2015P2 2016

MCL 2015 TBD

ALL 2015 TBD

CLL 2015 TBD

3 EGFRVIII CAR GBM 2011 2016

4 NY-ESO-1 TCR Solid Tumors 2013 2016

5 MAGE A3/A6 TCR Solid Tumors 2014 2016

6 MAGE A3 TCR Solid Tumors 2014 2016

7 HPV-16 E6 TCR Cervical, H&N 2014 2016

8 HPV-16 E7 TCR Cervical, H&N 2015 20161 Other than KTE-C19, clinical trials being conducted by the NCI pursuant to the CRADA2 FSE: first subject enrolled; expected for KTE-C19 and HPV-16 E73 Anticipated dates for initial data availability are provided